We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Europe Receives CE Marking for Fully Automated Lumipulse G SARS-CoV-2 S-IgG Assay

By LabMedica International staff writers
Posted on 19 Aug 2021
Print article
Image: Fujirebio Europe Receives CE Marking for Fully Automated Lumipulse G SARS-CoV-2 S-IgG Assay (Photo courtesy of Fujirebio Europe)
Image: Fujirebio Europe Receives CE Marking for Fully Automated Lumipulse G SARS-CoV-2 S-IgG Assay (Photo courtesy of Fujirebio Europe)
Fujirebio Europe (Gent, Belgium) has received the CE marking for its Lumipulse G SARS-CoV-2 S-IgG assay, a quantitative antibody assay for a fully automated CLEIA (chemiluminescent enzyme immunoassay) system.

The quantitative measurement of IgG antibodies to SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) can help in the assessment of immune response to the SARS-CoV-2 S protein. Detection of the IgG-type antibodies to SARS-CoV-2 Spike protein provides important information about a diagnosis of SARS-CoV-2 and confirmation of antibody acquisition for vaccination.

The Lumipulse G SARS-CoV-2 S-IgG assay will be available for use on the LUMIPULSE G1200 and LUMIPULSE G600II instruments. The LUMIPULSE G series are robust, fully automated CLEIA instruments. The LUMIPULSE G1200 and G600II have a throughput of respectively 120 and 60 tests per hour and allow laboratory personnel to randomly load samples as needed. CLEIA technology and automated testing provides increased sensitivity, reproducibility, and throughput.

With this new antibody test we provide a fully automated SARS-CoV-2 antigen and antibody testing solution, to be used on our LUMIPULSE® G series. We wish and expect that these innovations will have a positive impact on laboratory throughput of COVID-19 testing by consolidating immunoassay solutions,” said Christiaan De Wilde, CEO at Fujirebio Europe.


Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.